XCRP (Xcorporeal) Total Receivables: $0.10 Mil (As of Sep. 2009)


What is Xcorporeal Total Receivables?

Xcorporeal XCRP -99.00% Total Receivables is $0.10 Mil as of Sep. 2009.

Xcorporeal's Total Receivables for the quarter that ended in Sep. 2009 was $0.10 Mil.

Xcorporeal Total Receivables Historical Data

* Premium members only.

The historical data trend for Xcorporeal's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xcorporeal Total Receivables Chart

Xcorporeal Annual Data
Trend Feb99 Feb00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.09

Xcorporeal Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.09 0.09 0.09 0.10

Xcorporeal Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.10 Mil mean?
Xcorporeal (XCRP) has a Total Receivables of $0.10 Mil as of Sep. 2009. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Xcorporeal and its competitors.
Is Xcorporeal's Total Receivables too high?
Xcorporeal's current Total Receivables is $0.10 Mil.
How does Xcorporeal's Total Receivables compare to MFST and GTHP?
Xcorporeal's Total Receivables of $0.10 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Xcorporeal and its competitors. Xcorporeal's current Total Receivables is $0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xcorporeal stock overvalued right now?
Xcorporeal (XCRP) has a current Total Receivables of $0.10 Mil. The current Total Receivables is $0.10 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Xcorporeal (XCRP), the current Total Receivables is $0.10 Mil as of Sep. 2009. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xcorporeal Business Description

Address 80 Empire Drive, Lake Forest, CA, USA, 92630
Xcorporeal Inc is a medical device company, developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs.